AR124286A1 - Proteínas de unión a il-7 y su uso en tratamientos médicos - Google Patents
Proteínas de unión a il-7 y su uso en tratamientos médicosInfo
- Publication number
- AR124286A1 AR124286A1 ARP210103301A ARP210103301A AR124286A1 AR 124286 A1 AR124286 A1 AR 124286A1 AR P210103301 A ARP210103301 A AR P210103301A AR P210103301 A ARP210103301 A AR P210103301A AR 124286 A1 AR124286 A1 AR 124286A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- set forth
- binding
- binding protein
- binding proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000000704 Interleukin-7 Human genes 0.000 abstract 7
- 108010002586 Interleukin-7 Proteins 0.000 abstract 7
- 229940100994 interleukin-7 Drugs 0.000 abstract 7
- 102000023732 binding proteins Human genes 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 abstract 2
- 102000052622 human IL7 Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se proporcionan proteínas de unión a interleucina 7 (IL-7), composiciones farmacéuticas y su uso en el tratamiento o prevención de una enfermedad o afección. Reivindicación 1: Una proteína de unión a IL-7 que se une a uno o más residuos de aminoácidos dentro de la secuencia de aminoácidos establecida en la SEQ ID Nº 12 de IL-7 humana. Reivindicación 4: Una proteína de unión a IL-7 caracterizada porque se une a IL-7 humana adyacente a un sitio de unión a IL-7Ra, con una KD de aproximadamente 100 nM o menos medida por ensayo de resonancia de plasmón de superficie. Reivindicación 7: Una proteína de unión a IL-7 caracterizada porque comprende CDRH1 como se establece en la SEQ ID Nº 6, CDRH2 como se indica en la SEQ ID Nº 7, CDRH3 como se indica en la SEQ ID Nº 8, CDRL1 como se indica en la SEQ ID Nº 9, CDRL2 como se establece en la SEQ ID Nº 10 y CDRL3 como se establece en la SEQ ID Nº 11. Reivindicación 27: Una composición farmacéutica, caracterizada porque comprende un transportador o excipiente farmacéuticamente aceptable y una proteína de unión a IL-7 que exhibe unión para IL-7 en un epítopo que comprende al menos 5 aminoácidos contiguos de una secuencia establecida en la SEQ ID Nº 12 o la SEQ ID Nº 16.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120564P | 2020-12-02 | 2020-12-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124286A1 true AR124286A1 (es) | 2023-03-15 |
Family
ID=78844686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103301A AR124286A1 (es) | 2020-12-02 | 2021-11-30 | Proteínas de unión a il-7 y su uso en tratamientos médicos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11802150B2 (es) |
| EP (1) | EP4255928A1 (es) |
| JP (1) | JP2023551935A (es) |
| KR (1) | KR20230098288A (es) |
| CN (1) | CN116547002A (es) |
| AR (1) | AR124286A1 (es) |
| AU (1) | AU2021391493A1 (es) |
| CA (1) | CA3199648A1 (es) |
| CL (1) | CL2023001556A1 (es) |
| CO (1) | CO2023007851A2 (es) |
| IL (1) | IL303134A (es) |
| MX (1) | MX2023006294A (es) |
| TW (1) | TWI821804B (es) |
| WO (1) | WO2022117526A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129445A1 (es) * | 2022-05-27 | 2024-08-28 | Glaxosmithkline Ip Dev Ltd | USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| JP2008512353A (ja) | 2004-07-21 | 2008-04-24 | グライコフィ， インコーポレイテッド | 主にＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを含むイムノグロブリン |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
-
2021
- 2021-11-30 AR ARP210103301A patent/AR124286A1/es unknown
- 2021-11-30 CA CA3199648A patent/CA3199648A1/en active Pending
- 2021-11-30 EP EP21823820.2A patent/EP4255928A1/en active Pending
- 2021-11-30 MX MX2023006294A patent/MX2023006294A/es unknown
- 2021-11-30 IL IL303134A patent/IL303134A/en unknown
- 2021-11-30 US US17/538,431 patent/US11802150B2/en active Active
- 2021-11-30 CN CN202180081029.5A patent/CN116547002A/zh active Pending
- 2021-11-30 TW TW110144544A patent/TWI821804B/zh active
- 2021-11-30 KR KR1020237018159A patent/KR20230098288A/ko active Search and Examination
- 2021-11-30 JP JP2023533733A patent/JP2023551935A/ja active Pending
- 2021-11-30 AU AU2021391493A patent/AU2021391493A1/en active Pending
- 2021-11-30 WO PCT/EP2021/083465 patent/WO2022117526A1/en active Application Filing
-
2023
- 2023-05-31 CL CL2023001556A patent/CL2023001556A1/es unknown
- 2023-06-15 CO CONC2023/0007851A patent/CO2023007851A2/es unknown
- 2023-09-05 US US18/460,944 patent/US12122828B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023007851A2 (es) | 2023-06-30 |
| AU2021391493A1 (en) | 2023-06-08 |
| JP2023551935A (ja) | 2023-12-13 |
| US11802150B2 (en) | 2023-10-31 |
| US20240025988A1 (en) | 2024-01-25 |
| KR20230098288A (ko) | 2023-07-03 |
| MX2023006294A (es) | 2023-06-13 |
| AU2021391493A9 (en) | 2024-05-23 |
| WO2022117526A1 (en) | 2022-06-09 |
| IL303134A (en) | 2023-07-01 |
| TW202237183A (zh) | 2022-10-01 |
| CN116547002A (zh) | 2023-08-04 |
| US12122828B2 (en) | 2024-10-22 |
| CA3199648A1 (en) | 2022-06-09 |
| US20220169717A1 (en) | 2022-06-02 |
| TWI821804B (zh) | 2023-11-11 |
| CL2023001556A1 (es) | 2023-11-10 |
| EP4255928A1 (en) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| HRP20171499T1 (hr) | Protutijela za humani gdf8 | |
| AR127344A2 (es) | Conjugados anticuerpo-fármaco que comprenden agonistas de sting | |
| JP2024016177A5 (es) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2020500538A5 (es) | ||
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| JP2009511480A5 (es) | ||
| AR073770A1 (es) | Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| JP2015508762A5 (es) | ||
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| FI4045533T3 (fi) | Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2) | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| BR112022016695A2 (pt) | Anticorpo biespecífico ou fragmento de ligação do mesmo, polinucleotídeo, vetor, composição farmacêutica, molécula que se liga especificamente ao hla/ny-eso humano, seus usos, e métodos de produção de um anticorpo ou de uma molécula | |
| RU2017103679A (ru) | Способ ингибирования внутриклеточного активированного ras с помощью интакного антитела иммуноглобулинового типа, обладающего способностью к проникновению в цитозоль, и его применение | |
| JP2017520572A5 (es) | ||
| JP2018512124A5 (es) | ||
| JP2023015301A5 (es) | ||
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| PE20221865A1 (es) | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf |